Use of GLP-1 receptor agonists for the treatment of short bowel syndrome

a technology of glp-1 receptor and glp-1, which is applied in the field of glp1 receptor agonists, can solve the problems of severe diarrhea and nutritional deprivation, lack of absorption surface, lack of surface area in the remaining bowel, etc., and achieve the effect of normalizing bowel function and reducing the number of bowel movements

Active Publication Date: 2012-08-07
CEDARS SINAI MEDICAL CENT
View PDF6 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

SBS is a serious, often life-threatening, medical problem resulting in severe diarrhea and nutritional deprivation.
The removal may result in the lack of surface area in the remaining bowel to absorb enough nutrients from food.
The symptoms result from a lack of absorptive surface and loss of the braking mechanisms controlling the proximal gut.
Currently, there is no cure for short bowel syndrome and treatment options are not completely effective for all patients.
Other gastrointestinal disorders include spastic or hyperactive esophageal motor disorders which may limit the delivery of food and liquid, as well as cause painful symptoms.
Symptoms of achalasia include difficulty swallowing liquids and solids, regurgitation of food, chest pain, weight loss, heart burn and cough.
However, anti-reflux medications only reduce a risk factor for these conditions; medications to relax the muscles only provide relief to some patients and their effectiveness overall is not very good; and the use of antidepressants only treats the associated pain, rather than the abnormalities themselves.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0053]A patient was on total parenteral nutrition with only two feet of small bowel. Typically, less than three feet of small bowel is too little to survive on food alone. The patient was having nutritional compromise. He would experience diarrhea within 15 minutes of eating. Normal eating habits resulted in experiencing more than 10 bowel movements a day. Without the i.v. feedings, he would lose ten pounds in one week due to dehydration. In July 2006, the patient was administered Byetta® exenatide and on the same day of administration, he did not experience a bowel movement until six hours after a meal. Since the commencement of treatment with Byetta® exenatide, he has not required i.v. feeding and experiences 1-2 solid bowel movements a day. The patient's bowel health returned to normal and returned to work within one week of starting treatment with Byetta® exenatide. The patient's nutritional status improved dramatically and has normalized. The patient has been using Byetta® exen...

example 2

[0054]Short bowel syndrome (SBS) subjects were selected based on clinical symptoms and history of greater than 50% distal small bowel resection. Before beginning exenatide treatment, each patient completed a questionnaire documenting stool frequency and consistency. In addition, SBS symptoms, CBC, chemistries and BMI were also obtained. An antroduodenal manometry study was performed during fasting, after exenatide, and after a subsequent test meal. Each patient was then started on exenatide 5 to 10 mcg subcutaneously twice a day. Over the following month the parameters measured at baseline were repeated.

example 3

[0055]The subjects consisted of 4 males and 1 female, ages 46 to 69 (mean: 57.2). At baseline, all patients had severe diarrhea that ranged from 7 to 15 bowel movements per day, often occurring within 15 minutes of eating. After exenatide treatment, all 5 patients had an immediate improvement in bowel frequency and form. In the most severely affected patient, the bowel movements reduced from 15 watery bowel movements per day to 2-3 formed stool. In all subjects, bowel movements were no longer meal related and often occurred hours after any meal. At baseline nutritional parameters were stable due to total parenteral nutrition (TPN) in most cases (n=3). However, after exenatide treatment, all 3 patients no longer needed TPN. Despite the lack of TPN, no weight loss or biochemical nutritional deterioration was observed in any case. Previous attempts at ceasing TPN had resulted in immediate and life-threatening dehydraton and malnutrition. Using normal bowel function as a goal, subjects ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
number of bowel movementsaaaaaaaaaa
surface areaaaaaaaaaaa
Login to view more

Abstract

The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.

Description

[0001]This application is the National Phase of International Application PCT / US08 / 61417, filed Apr. 24, 2008, which designated the U.S. and that International Application was published under PCT Article 21(2) in English. This application also includes a claim of priority under 35 U.S.C. §119(e) to U.S. provisional patent application No. 60 / 914,687, filed Apr. 27, 2007, and U.S. provisional patent application No. 60 / 915,901, filed May 3, 2007.FIELD OF INVENTION[0002]This invention relates to the use of GLP-1 receptor agonists to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.BACKGROUND[0003]All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K38/26A61K38/00
CPCA61K38/26A61P1/00A61P1/06
Inventor PIMENTEL, MARKSOFFER, EDY E.CONKLIN, JEFFREY
Owner CEDARS SINAI MEDICAL CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap